{"id":"treatment-with-tirzapatide","safety":{"commonSideEffects":[{"rate":"25-33","effect":"Nausea"},{"rate":"7-12","effect":"Vomiting"},{"rate":"19-23","effect":"Diarrhea"},{"rate":"16-22","effect":"Constipation"},{"rate":"13-17","effect":"Abdominal pain"},{"rate":"5-8","effect":"Injection site reactions"},{"rate":"null","effect":"Hypoglycemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tirzapatide activates both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, leading to glucose-dependent insulin secretion, suppression of glucagon, and delayed gastric emptying. This dual mechanism results in improved glycemic control and weight loss in patients with type 2 diabetes. The GIP component provides additional metabolic benefits beyond traditional GLP-1 monotherapy.","oneSentence":"Tirzapatide is a dual GLP-1 and GIP receptor agonist that stimulates insulin secretion and reduces glucagon levels in response to elevated blood glucose.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:14:16.858Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Chronic weight management in adults with obesity or overweight"}]},"trialDetails":[{"nctId":"NCT07354880","phase":"PHASE4","title":"Effect of Tirzepatide on Cardiovascular and Metabolic Parameters in Obese Adult Patients With Congenital Heart Disease","status":"NOT_YET_RECRUITING","sponsor":"University Medical Centre Ljubljana","startDate":"2026-01-20","conditions":"Obesity & Overweight, Adult Congenital Heart Disease","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Treatment with tirzapatide","genericName":"Treatment with tirzapatide","companyName":"University Medical Centre Ljubljana","companyId":"university-medical-centre-ljubljana","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tirzapatide is a dual GLP-1 and GIP receptor agonist that stimulates insulin secretion and reduces glucagon levels in response to elevated blood glucose. Used for Type 2 diabetes mellitus, Chronic weight management in adults with obesity or overweight.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}